Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

SELL
$26.24 - $39.63 $8,921 - $13,474
-340 Reduced 2.28%
14,564 $572,000
Q1 2023

May 02, 2023

BUY
$18.67 - $24.56 $5,526 - $7,269
296 Added 2.03%
14,904 $362,000
Q4 2022

Feb 10, 2023

BUY
$17.24 - $23.95 $2,275 - $3,161
132 Added 0.91%
14,608 $312,000
Q4 2022

Feb 09, 2023

SELL
$17.24 - $23.95 $267,840 - $372,087
-15,536 Reduced 51.77%
14,476 $309,000
Q3 2022

Nov 02, 2022

SELL
$9.4 - $18.59 $140,454 - $277,771
-14,942 Reduced 33.24%
30,012 $538,000
Q2 2022

Aug 01, 2022

BUY
$9.12 - $18.9 $32,075 - $66,471
3,517 Added 8.49%
44,954 $432,000
Q1 2022

May 04, 2022

BUY
$12.15 - $16.83 $171,497 - $237,555
14,115 Added 51.66%
41,437 $574,000
Q4 2021

Feb 07, 2022

BUY
$13.83 - $18.78 $187,991 - $255,276
13,593 Added 99.01%
27,322 $457,000
Q3 2021

Nov 02, 2021

BUY
$7.07 - $17.5 $15,617 - $38,657
2,209 Added 19.18%
13,729 $223,000
Q2 2021

Aug 03, 2021

SELL
$5.69 - $7.17 $6,947 - $8,754
-1,221 Reduced 9.58%
11,520 $73,000
Q1 2021

May 04, 2021

SELL
$5.08 - $6.89 $2,352 - $3,190
-463 Reduced 3.51%
12,741 $79,000
Q4 2020

Feb 01, 2021

SELL
$5.65 - $7.66 $158 - $214
-28 Reduced 0.21%
13,204 $91,000
Q3 2020

Nov 09, 2020

BUY
$4.01 - $6.29 $4,034 - $6,327
1,006 Added 8.23%
13,232 $75,000
Q2 2020

Aug 07, 2020

BUY
$3.06 - $6.6 $17,396 - $37,521
5,685 Added 86.91%
12,226 $62,000
Q1 2020

May 04, 2020

SELL
$2.83 - $8.44 $933 - $2,785
-330 Reduced 4.8%
6,541 $23,000
Q4 2019

Feb 04, 2020

BUY
$0.93 - $8.58 $847 - $7,816
911 Added 15.29%
6,871 $46,000
Q3 2019

Nov 12, 2019

BUY
$1.09 - $1.29 $6,496 - $7,688
5,960 New
5,960 $7,000

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.